Private Portfolio Partners LLC raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 16.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,189 shares of the company's stock after buying an additional 459 shares during the period. Private Portfolio Partners LLC's holdings in Eli Lilly and Company were worth $2,462,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of LLY. Principal Financial Group Inc. lifted its stake in shares of Eli Lilly and Company by 5.3% in the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock worth $1,070,698,000 after buying an additional 60,306 shares in the last quarter. Benjamin Edwards Inc. lifted its stake in Eli Lilly and Company by 316.6% in the 3rd quarter. Benjamin Edwards Inc. now owns 13,463 shares of the company's stock worth $11,943,000 after purchasing an additional 10,231 shares in the last quarter. Hilltop Holdings Inc. boosted its holdings in shares of Eli Lilly and Company by 118.4% during the 3rd quarter. Hilltop Holdings Inc. now owns 7,328 shares of the company's stock worth $6,492,000 after purchasing an additional 3,972 shares during the last quarter. Harmony Asset Management LLC grew its position in shares of Eli Lilly and Company by 3.2% in the third quarter. Harmony Asset Management LLC now owns 5,773 shares of the company's stock valued at $5,115,000 after purchasing an additional 178 shares in the last quarter. Finally, Investment Management Corp of Ontario grew its position in shares of Eli Lilly and Company by 55.1% in the third quarter. Investment Management Corp of Ontario now owns 29,382 shares of the company's stock valued at $26,031,000 after purchasing an additional 10,442 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research firms have weighed in on LLY. Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a research note on Thursday, January 16th. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research report on Friday, January 17th. Morgan Stanley set a $1,146.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, March 6th. Bank of America reiterated a "buy" rating and issued a $997.00 target price on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Finally, Truist Financial raised their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a report on Monday, February 3rd. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus target price of $1,009.72.
Get Our Latest Stock Report on LLY
Insider Transactions at Eli Lilly and Company
In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.13% of the company's stock.
Eli Lilly and Company Stock Up 1.8 %
Shares of LLY stock traded up $14.34 during trading on Wednesday, reaching $819.57. The company's stock had a trading volume of 2,678,114 shares, compared to its average volume of 3,311,810. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a 1-year low of $711.40 and a 1-year high of $972.53. The company has a market capitalization of $777.09 billion, a price-to-earnings ratio of 69.99, a P/E/G ratio of 1.40 and a beta of 0.34. The stock's 50-day moving average price is $848.85 and its 200 day moving average price is $834.05.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.
Eli Lilly and Company announced that its Board of Directors has authorized a share buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's management believes its shares are undervalued.
Eli Lilly and Company Company Profile
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Further Reading
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
